Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?Benzinga · Oct 13, 2026
Alaunos Therapeutics Announces Acquisition of Velaris TherapeuticsGlobeNewsWire · Oct 13, 2026
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.PRNewsWire · Oct 13, 2026
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rulesGlobeNewsWire · Sep 18, 2026
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving PremarketBenzinga · Sep 18, 2026Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | – | -$0.41 | |
| May 15, 2026 | – | -$0.59 | |
| Mar 31, 2026 | -$3.69 | -$0.40 | Beat |
| Nov 14, 2025 | -$4.90 | -$0.55 | Beat |
| Aug 14, 2025 | -$5.33 | -$0.63 | Beat |
| May 15, 2025 | -$6.44 | -$0.67 | Beat |